To the Editor:
We read with great interest the article by Marcucci et al in a recent issue of Circulation. 1 The authors concluded that a residual platelet reactivity (RPR) cutoff value Ն240 reaction units identified patients with a significantly higher risk of cardiovascular death and nonfatal myocardial infarction. Considering the potential clinical implications of this attractive study, addressing some methodological issues would be appreciated.
Although only patients with acute coronary syndrome were enrolled, the study population is somewhat heterogeneous because patients with ST-elevation myocardial infarction (STEMI), non-STEMI, and unstable angina were included. Patients with STEMI suffer from acute thrombus formation leading to total coronary artery occlusion. Greater platelet reactivity should be expected in this clinical condition. In the present study, 1 a similar proportion of patients with STEMI were found in the high-RPR (28.7%) and low-RPR (27.5%) groups. Did the authors analyze differences in RPR mean values between patients with STEMI and the rest of the study population? It would be interesting to know whether the proposed cutoff value might be influenced by potential differences in RPR in different clinical conditions. Geisler et al 2 showed different posttreatment platelet reactivity and response to dual antiplatelet therapy between patients with stable angina and those with acute coronary syndrome, supporting the concept that "the more severe the clinical condition, the higher the platelet reactivity."
In the present study, RPR measurement was performed in some patients within 24 hours after 600 mg clopidogrel loading dose and in other patients (those who received glycoprotein IIb/IIIa inhibitors) 6 days after clopidogrel loading dose. Did the authors observe different RPR mean values between these 2 groups of patients? After intensive treatment, a delay in the measurement of platelet function to a subacute phase of the coronary event might influence platelet reactivity values.
In a series of patients with non-STEMI and unstable angina, 3 we identified a RPR cutoff value of 175 reaction units as a predictor of 1-year adverse cardiovascular events. This cutoff value differs from that proposed by Marcucci et al 1 and other authors. 4, 5 Differences in the composition of the study population and antithrombotic therapies can explain the difference, as does the prolonged period (69Ϯ30 hour) of intensive treatment before the angiography in our study group.
RPR is recognized as a better estimate for thrombotic risk than the inhibition of platelet aggregation, given that the latter does not take into account the absolute level of platelet reactivity. We absolutely agree with the authors that RPR is able to identify patients at higher risk of long-term adverse clinical events. Due to the limitations of available clinical studies and platelet function tests, proposed cutoff values should be applied with caution in different clinical conditions. Definitive data from large-scale clinical trials are needed to confirm these differences and to support a change in antiplatelet therapy based on the measurement of the platelet reactivity.
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